This site uses cookies to deliver our services and to show you relevant ads and presentations. By clicking on "Accept", you acknowledge that you have read and understand our Cookie Policy , Privacy Policy , and our Terms of Use.
X

Download Cervical Cancer Free North Carolina PowerPoint Presentation


Login   OR  Register
X


Iframe embed code :



Presentation url :

X

Description :

Available Cervical Cancer Free North Carolina powerpoint presentation for free download which is uploaded by search an active user in belonging ppt presentation Health & Wellness category.

Tags :

Cervical Cancer Free North Carolina

Home / Health & Wellness / Health & Wellness Presentations / Cervical Cancer Free North Carolina PowerPoint Presentation

Cervical Cancer Free North Carolina PowerPoint Presentation

Ppt Presentation Embed Code   Zoom Ppt Presentation

About This Presentation


Description : Available Cervical Cancer Free North Carolina powerpoint presentation for free download which is upl... Read More

Tags : Cervical Cancer Free North Carolina

Published on : Feb 24, 2014
Views : 358 | Downloads : 0


Download Now

Share on Social Media

             

PowerPoint is the world's most popular presentation software which can let you create professional Cervical Cancer Free North Carolina powerpoint presentation easily and in no time. This helps you give your presentation on Cervical Cancer Free North Carolina in a conference, a school lecture, a business proposal, in a webinar and business and professional representations.

The uploader spent his/her valuable time to create this Cervical Cancer Free North Carolina powerpoint presentation slides, to share his/her useful content with the world. This ppt presentation uploaded by onlinesearch in this Health & Wellness category is available for free download,and can be used according to your industries like finance, marketing, education, health and many more.

SlidesFinder.com provides a platform to marketers, presenters and educationists along with being the preferred search engine for professional PowerPoint presentations on the Internet to upload their Cervical Cancer Free North Carolina ppt presentation slides to help them BUILD THEIR CROWD!!

User Presentation
Related Presentation
Free PowerPoint Templates
Slide 1 - Jennifer S. Smith University of North Carolina JenniferS@unc.edu Cervical Cancer-Free America Initiative Overview Changing the Dialogue about Cervical Cancer Prevention
Slide 2 - Jennifer S. Smith University of North Carolina JenniferS@unc.edu Cervical Cancer-Free America Initiative Overview Changing the Dialogue about Cervical Cancer Prevention Carolina Framework for Action against Cervical Cancer There are four key challenges to eradication of cervical cancer that a comprehensive public health strategy can address: HPV infection Lack of screening Screening errors Not receiving follow-up care for abnormal Pap smear results Brewer and Smith
Slide 3 - Jennifer S. Smith University of North Carolina JenniferS@unc.edu Cervical Cancer-Free America Initiative Overview Changing the Dialogue about Cervical Cancer Prevention Carolina Framework for Action against Cervical Cancer There are four key challenges to eradication of cervical cancer that a comprehensive public health strategy can address: HPV infection Lack of screening Screening errors Not receiving follow-up care for abnormal Pap smear results Brewer and Smith HPV virus-like particles (VLPs): Basis of HPV vaccination For Prevention of Cervical Cancer: Persistent HPV 16/18 infections HPV 16/18 abnormal pap smear
Slide 4 - Jennifer S. Smith University of North Carolina JenniferS@unc.edu Cervical Cancer-Free America Initiative Overview Changing the Dialogue about Cervical Cancer Prevention Carolina Framework for Action against Cervical Cancer There are four key challenges to eradication of cervical cancer that a comprehensive public health strategy can address: HPV infection Lack of screening Screening errors Not receiving follow-up care for abnormal Pap smear results Brewer and Smith HPV virus-like particles (VLPs): Basis of HPV vaccination For Prevention of Cervical Cancer: Persistent HPV 16/18 infections HPV 16/18 abnormal pap smear HPV Types by Cervical Status: Potential Impact of 16/18 Vaccine ~70% ~50% ~14-25% HPV Type Specific Prevalence in All Cases ICC data: Smith et al. Int Journal of Cancer, 2007, 121 (3), 621-32. HSIL data: Smith et al. Int Journal of Cancer, 2007, 121 (3), 621-32. LSIL data: Clifford et al. Cancer Epidemiol Biomarkers. 2005;14:1157-1164
Slide 5 - Jennifer S. Smith University of North Carolina JenniferS@unc.edu Cervical Cancer-Free America Initiative Overview Changing the Dialogue about Cervical Cancer Prevention Carolina Framework for Action against Cervical Cancer There are four key challenges to eradication of cervical cancer that a comprehensive public health strategy can address: HPV infection Lack of screening Screening errors Not receiving follow-up care for abnormal Pap smear results Brewer and Smith HPV virus-like particles (VLPs): Basis of HPV vaccination For Prevention of Cervical Cancer: Persistent HPV 16/18 infections HPV 16/18 abnormal pap smear HPV Types by Cervical Status: Potential Impact of 16/18 Vaccine ~70% ~50% ~14-25% HPV Type Specific Prevalence in All Cases ICC data: Smith et al. Int Journal of Cancer, 2007, 121 (3), 621-32. HSIL data: Smith et al. Int Journal of Cancer, 2007, 121 (3), 621-32. LSIL data: Clifford et al. Cancer Epidemiol Biomarkers. 2005;14:1157-1164 Optimal to Vaccinate Adolescent Girls before Sexual Debut 1- Hypothetical distribution of HPV prevalence in EU modeled after data available in the US and Canada 35 30 25 20 15 10 5 Age (years) % Estimated start of sexual life 0 5 10 15 20 25 30 35 40 45 50 55 60 65 70 75 Frequency Papillomavirus Infection (all types)
Slide 6 - Jennifer S. Smith University of North Carolina JenniferS@unc.edu Cervical Cancer-Free America Initiative Overview Changing the Dialogue about Cervical Cancer Prevention Carolina Framework for Action against Cervical Cancer There are four key challenges to eradication of cervical cancer that a comprehensive public health strategy can address: HPV infection Lack of screening Screening errors Not receiving follow-up care for abnormal Pap smear results Brewer and Smith HPV virus-like particles (VLPs): Basis of HPV vaccination For Prevention of Cervical Cancer: Persistent HPV 16/18 infections HPV 16/18 abnormal pap smear HPV Types by Cervical Status: Potential Impact of 16/18 Vaccine ~70% ~50% ~14-25% HPV Type Specific Prevalence in All Cases ICC data: Smith et al. Int Journal of Cancer, 2007, 121 (3), 621-32. HSIL data: Smith et al. Int Journal of Cancer, 2007, 121 (3), 621-32. LSIL data: Clifford et al. Cancer Epidemiol Biomarkers. 2005;14:1157-1164 Optimal to Vaccinate Adolescent Girls before Sexual Debut 1- Hypothetical distribution of HPV prevalence in EU modeled after data available in the US and Canada 35 30 25 20 15 10 5 Age (years) % Estimated start of sexual life 0 5 10 15 20 25 30 35 40 45 50 55 60 65 70 75 Frequency Papillomavirus Infection (all types) Prophylactic HPV Vaccine Approved for Adolescent Girls *Routine vaccination for 11-12 year old females
Slide 7 - Jennifer S. Smith University of North Carolina JenniferS@unc.edu Cervical Cancer-Free America Initiative Overview Changing the Dialogue about Cervical Cancer Prevention Carolina Framework for Action against Cervical Cancer There are four key challenges to eradication of cervical cancer that a comprehensive public health strategy can address: HPV infection Lack of screening Screening errors Not receiving follow-up care for abnormal Pap smear results Brewer and Smith HPV virus-like particles (VLPs): Basis of HPV vaccination For Prevention of Cervical Cancer: Persistent HPV 16/18 infections HPV 16/18 abnormal pap smear HPV Types by Cervical Status: Potential Impact of 16/18 Vaccine ~70% ~50% ~14-25% HPV Type Specific Prevalence in All Cases ICC data: Smith et al. Int Journal of Cancer, 2007, 121 (3), 621-32. HSIL data: Smith et al. Int Journal of Cancer, 2007, 121 (3), 621-32. LSIL data: Clifford et al. Cancer Epidemiol Biomarkers. 2005;14:1157-1164 Optimal to Vaccinate Adolescent Girls before Sexual Debut 1- Hypothetical distribution of HPV prevalence in EU modeled after data available in the US and Canada 35 30 25 20 15 10 5 Age (years) % Estimated start of sexual life 0 5 10 15 20 25 30 35 40 45 50 55 60 65 70 75 Frequency Papillomavirus Infection (all types) Prophylactic HPV Vaccine Approved for Adolescent Girls *Routine vaccination for 11-12 year old females Females aged 13-17 years US 2009: 44.3% (42.4%-46.1%) for 1+ dose 26.7% (25.2%-28.3%) for 3 doses completed August 20, 2010 / 59(32);1018-1023 HPV Vaccine Coverage National Immunization Survey-Teen
Slide 8 - Jennifer S. Smith University of North Carolina JenniferS@unc.edu Cervical Cancer-Free America Initiative Overview Changing the Dialogue about Cervical Cancer Prevention Carolina Framework for Action against Cervical Cancer There are four key challenges to eradication of cervical cancer that a comprehensive public health strategy can address: HPV infection Lack of screening Screening errors Not receiving follow-up care for abnormal Pap smear results Brewer and Smith HPV virus-like particles (VLPs): Basis of HPV vaccination For Prevention of Cervical Cancer: Persistent HPV 16/18 infections HPV 16/18 abnormal pap smear HPV Types by Cervical Status: Potential Impact of 16/18 Vaccine ~70% ~50% ~14-25% HPV Type Specific Prevalence in All Cases ICC data: Smith et al. Int Journal of Cancer, 2007, 121 (3), 621-32. HSIL data: Smith et al. Int Journal of Cancer, 2007, 121 (3), 621-32. LSIL data: Clifford et al. Cancer Epidemiol Biomarkers. 2005;14:1157-1164 Optimal to Vaccinate Adolescent Girls before Sexual Debut 1- Hypothetical distribution of HPV prevalence in EU modeled after data available in the US and Canada 35 30 25 20 15 10 5 Age (years) % Estimated start of sexual life 0 5 10 15 20 25 30 35 40 45 50 55 60 65 70 75 Frequency Papillomavirus Infection (all types) Prophylactic HPV Vaccine Approved for Adolescent Girls *Routine vaccination for 11-12 year old females Females aged 13-17 years US 2009: 44.3% (42.4%-46.1%) for 1+ dose 26.7% (25.2%-28.3%) for 3 doses completed August 20, 2010 / 59(32);1018-1023 HPV Vaccine Coverage National Immunization Survey-Teen Continued Need for Screening Following HPV Vaccination ~70% ~50% ~14-25% HPV Type Specific Prevalence in All Cases ICC data: Smith et al. Int Journal of Cancer, 2007, 121 (3), 621-32. HSIL data: Smith et al. Int Journal of Cancer, 2007, 121 (3), 621-32. LSIL data: Clifford et al. Cancer Epidemiol Biomarkers. 2005;14:1157-1164
Slide 9 - Jennifer S. Smith University of North Carolina JenniferS@unc.edu Cervical Cancer-Free America Initiative Overview Changing the Dialogue about Cervical Cancer Prevention Carolina Framework for Action against Cervical Cancer There are four key challenges to eradication of cervical cancer that a comprehensive public health strategy can address: HPV infection Lack of screening Screening errors Not receiving follow-up care for abnormal Pap smear results Brewer and Smith HPV virus-like particles (VLPs): Basis of HPV vaccination For Prevention of Cervical Cancer: Persistent HPV 16/18 infections HPV 16/18 abnormal pap smear HPV Types by Cervical Status: Potential Impact of 16/18 Vaccine ~70% ~50% ~14-25% HPV Type Specific Prevalence in All Cases ICC data: Smith et al. Int Journal of Cancer, 2007, 121 (3), 621-32. HSIL data: Smith et al. Int Journal of Cancer, 2007, 121 (3), 621-32. LSIL data: Clifford et al. Cancer Epidemiol Biomarkers. 2005;14:1157-1164 Optimal to Vaccinate Adolescent Girls before Sexual Debut 1- Hypothetical distribution of HPV prevalence in EU modeled after data available in the US and Canada 35 30 25 20 15 10 5 Age (years) % Estimated start of sexual life 0 5 10 15 20 25 30 35 40 45 50 55 60 65 70 75 Frequency Papillomavirus Infection (all types) Prophylactic HPV Vaccine Approved for Adolescent Girls *Routine vaccination for 11-12 year old females Females aged 13-17 years US 2009: 44.3% (42.4%-46.1%) for 1+ dose 26.7% (25.2%-28.3%) for 3 doses completed August 20, 2010 / 59(32);1018-1023 HPV Vaccine Coverage National Immunization Survey-Teen Continued Need for Screening Following HPV Vaccination ~70% ~50% ~14-25% HPV Type Specific Prevalence in All Cases ICC data: Smith et al. Int Journal of Cancer, 2007, 121 (3), 621-32. HSIL data: Smith et al. Int Journal of Cancer, 2007, 121 (3), 621-32. LSIL data: Clifford et al. Cancer Epidemiol Biomarkers. 2005;14:1157-1164 Decrease in Cervical Cancer Mortality Following Introduction of Pap Test in the United States 1. OBGYN.net. Available at: http://www.obgyn.net/displayarticle.asp?page=/yw/articles/braun_PAP 2. American Cancer Society. Cancer Facts & Figures. Available at: http://www.cancer.org/
Slide 10 - Jennifer S. Smith University of North Carolina JenniferS@unc.edu Cervical Cancer-Free America Initiative Overview Changing the Dialogue about Cervical Cancer Prevention Carolina Framework for Action against Cervical Cancer There are four key challenges to eradication of cervical cancer that a comprehensive public health strategy can address: HPV infection Lack of screening Screening errors Not receiving follow-up care for abnormal Pap smear results Brewer and Smith HPV virus-like particles (VLPs): Basis of HPV vaccination For Prevention of Cervical Cancer: Persistent HPV 16/18 infections HPV 16/18 abnormal pap smear HPV Types by Cervical Status: Potential Impact of 16/18 Vaccine ~70% ~50% ~14-25% HPV Type Specific Prevalence in All Cases ICC data: Smith et al. Int Journal of Cancer, 2007, 121 (3), 621-32. HSIL data: Smith et al. Int Journal of Cancer, 2007, 121 (3), 621-32. LSIL data: Clifford et al. Cancer Epidemiol Biomarkers. 2005;14:1157-1164 Optimal to Vaccinate Adolescent Girls before Sexual Debut 1- Hypothetical distribution of HPV prevalence in EU modeled after data available in the US and Canada 35 30 25 20 15 10 5 Age (years) % Estimated start of sexual life 0 5 10 15 20 25 30 35 40 45 50 55 60 65 70 75 Frequency Papillomavirus Infection (all types) Prophylactic HPV Vaccine Approved for Adolescent Girls *Routine vaccination for 11-12 year old females Females aged 13-17 years US 2009: 44.3% (42.4%-46.1%) for 1+ dose 26.7% (25.2%-28.3%) for 3 doses completed August 20, 2010 / 59(32);1018-1023 HPV Vaccine Coverage National Immunization Survey-Teen Continued Need for Screening Following HPV Vaccination ~70% ~50% ~14-25% HPV Type Specific Prevalence in All Cases ICC data: Smith et al. Int Journal of Cancer, 2007, 121 (3), 621-32. HSIL data: Smith et al. Int Journal of Cancer, 2007, 121 (3), 621-32. LSIL data: Clifford et al. Cancer Epidemiol Biomarkers. 2005;14:1157-1164 Decrease in Cervical Cancer Mortality Following Introduction of Pap Test in the United States 1. OBGYN.net. Available at: http://www.obgyn.net/displayarticle.asp?page=/yw/articles/braun_PAP 2. American Cancer Society. Cancer Facts & Figures. Available at: http://www.cancer.org/ Sensitivity of Cervical Cancer Screening Methods Naucler P, et al. JNCI. 2009;101:88-99.
Slide 11 - Jennifer S. Smith University of North Carolina JenniferS@unc.edu Cervical Cancer-Free America Initiative Overview Changing the Dialogue about Cervical Cancer Prevention Carolina Framework for Action against Cervical Cancer There are four key challenges to eradication of cervical cancer that a comprehensive public health strategy can address: HPV infection Lack of screening Screening errors Not receiving follow-up care for abnormal Pap smear results Brewer and Smith HPV virus-like particles (VLPs): Basis of HPV vaccination For Prevention of Cervical Cancer: Persistent HPV 16/18 infections HPV 16/18 abnormal pap smear HPV Types by Cervical Status: Potential Impact of 16/18 Vaccine ~70% ~50% ~14-25% HPV Type Specific Prevalence in All Cases ICC data: Smith et al. Int Journal of Cancer, 2007, 121 (3), 621-32. HSIL data: Smith et al. Int Journal of Cancer, 2007, 121 (3), 621-32. LSIL data: Clifford et al. Cancer Epidemiol Biomarkers. 2005;14:1157-1164 Optimal to Vaccinate Adolescent Girls before Sexual Debut 1- Hypothetical distribution of HPV prevalence in EU modeled after data available in the US and Canada 35 30 25 20 15 10 5 Age (years) % Estimated start of sexual life 0 5 10 15 20 25 30 35 40 45 50 55 60 65 70 75 Frequency Papillomavirus Infection (all types) Prophylactic HPV Vaccine Approved for Adolescent Girls *Routine vaccination for 11-12 year old females Females aged 13-17 years US 2009: 44.3% (42.4%-46.1%) for 1+ dose 26.7% (25.2%-28.3%) for 3 doses completed August 20, 2010 / 59(32);1018-1023 HPV Vaccine Coverage National Immunization Survey-Teen Continued Need for Screening Following HPV Vaccination ~70% ~50% ~14-25% HPV Type Specific Prevalence in All Cases ICC data: Smith et al. Int Journal of Cancer, 2007, 121 (3), 621-32. HSIL data: Smith et al. Int Journal of Cancer, 2007, 121 (3), 621-32. LSIL data: Clifford et al. Cancer Epidemiol Biomarkers. 2005;14:1157-1164 Decrease in Cervical Cancer Mortality Following Introduction of Pap Test in the United States 1. OBGYN.net. Available at: http://www.obgyn.net/displayarticle.asp?page=/yw/articles/braun_PAP 2. American Cancer Society. Cancer Facts & Figures. Available at: http://www.cancer.org/ Sensitivity of Cervical Cancer Screening Methods Naucler P, et al. JNCI. 2009;101:88-99. 30-64 Years 21-29 Years <21 Years No routine Pap smear Pap Smear Guidelines: 2009 American College of Obstetrics and Gynecology Pap smear every 3 years ..if patient has had 3 or more normal Pap results in a row, no abnormal test results in 10 years, and lacks other risk factors.* *History of cervical cancer or DES in utero, HIV positive, immunosuppression, or other risk factors for acquiring STDs. Bi-annual Pap smear ACOG Practice Bulletin No. 109. Obstet Gynecol. 2009;114:1409-20. ≥65 Years Consider discontinuing Pap smear at 65 or 70 years ..if patient has had 3 or more normal Pap results in a row, no abnormal test results in 10 years, and lacks other risk factors.*
Slide 12 - Jennifer S. Smith University of North Carolina JenniferS@unc.edu Cervical Cancer-Free America Initiative Overview Changing the Dialogue about Cervical Cancer Prevention Carolina Framework for Action against Cervical Cancer There are four key challenges to eradication of cervical cancer that a comprehensive public health strategy can address: HPV infection Lack of screening Screening errors Not receiving follow-up care for abnormal Pap smear results Brewer and Smith HPV virus-like particles (VLPs): Basis of HPV vaccination For Prevention of Cervical Cancer: Persistent HPV 16/18 infections HPV 16/18 abnormal pap smear HPV Types by Cervical Status: Potential Impact of 16/18 Vaccine ~70% ~50% ~14-25% HPV Type Specific Prevalence in All Cases ICC data: Smith et al. Int Journal of Cancer, 2007, 121 (3), 621-32. HSIL data: Smith et al. Int Journal of Cancer, 2007, 121 (3), 621-32. LSIL data: Clifford et al. Cancer Epidemiol Biomarkers. 2005;14:1157-1164 Optimal to Vaccinate Adolescent Girls before Sexual Debut 1- Hypothetical distribution of HPV prevalence in EU modeled after data available in the US and Canada 35 30 25 20 15 10 5 Age (years) % Estimated start of sexual life 0 5 10 15 20 25 30 35 40 45 50 55 60 65 70 75 Frequency Papillomavirus Infection (all types) Prophylactic HPV Vaccine Approved for Adolescent Girls *Routine vaccination for 11-12 year old females Females aged 13-17 years US 2009: 44.3% (42.4%-46.1%) for 1+ dose 26.7% (25.2%-28.3%) for 3 doses completed August 20, 2010 / 59(32);1018-1023 HPV Vaccine Coverage National Immunization Survey-Teen Continued Need for Screening Following HPV Vaccination ~70% ~50% ~14-25% HPV Type Specific Prevalence in All Cases ICC data: Smith et al. Int Journal of Cancer, 2007, 121 (3), 621-32. HSIL data: Smith et al. Int Journal of Cancer, 2007, 121 (3), 621-32. LSIL data: Clifford et al. Cancer Epidemiol Biomarkers. 2005;14:1157-1164 Decrease in Cervical Cancer Mortality Following Introduction of Pap Test in the United States 1. OBGYN.net. Available at: http://www.obgyn.net/displayarticle.asp?page=/yw/articles/braun_PAP 2. American Cancer Society. Cancer Facts & Figures. Available at: http://www.cancer.org/ Sensitivity of Cervical Cancer Screening Methods Naucler P, et al. JNCI. 2009;101:88-99. 30-64 Years 21-29 Years <21 Years No routine Pap smear Pap Smear Guidelines: 2009 American College of Obstetrics and Gynecology Pap smear every 3 years ..if patient has had 3 or more normal Pap results in a row, no abnormal test results in 10 years, and lacks other risk factors.* *History of cervical cancer or DES in utero, HIV positive, immunosuppression, or other risk factors for acquiring STDs. Bi-annual Pap smear ACOG Practice Bulletin No. 109. Obstet Gynecol. 2009;114:1409-20. ≥65 Years Consider discontinuing Pap smear at 65 or 70 years ..if patient has had 3 or more normal Pap results in a row, no abnormal test results in 10 years, and lacks other risk factors.* We can Change the Dialogue We can End Cervical Cancer Policy Makers Vaccination Screening We can Effect Real Change at the State-Level
Slide 13 - Jennifer S. Smith University of North Carolina JenniferS@unc.edu Cervical Cancer-Free America Initiative Overview Changing the Dialogue about Cervical Cancer Prevention Carolina Framework for Action against Cervical Cancer There are four key challenges to eradication of cervical cancer that a comprehensive public health strategy can address: HPV infection Lack of screening Screening errors Not receiving follow-up care for abnormal Pap smear results Brewer and Smith HPV virus-like particles (VLPs): Basis of HPV vaccination For Prevention of Cervical Cancer: Persistent HPV 16/18 infections HPV 16/18 abnormal pap smear HPV Types by Cervical Status: Potential Impact of 16/18 Vaccine ~70% ~50% ~14-25% HPV Type Specific Prevalence in All Cases ICC data: Smith et al. Int Journal of Cancer, 2007, 121 (3), 621-32. HSIL data: Smith et al. Int Journal of Cancer, 2007, 121 (3), 621-32. LSIL data: Clifford et al. Cancer Epidemiol Biomarkers. 2005;14:1157-1164 Optimal to Vaccinate Adolescent Girls before Sexual Debut 1- Hypothetical distribution of HPV prevalence in EU modeled after data available in the US and Canada 35 30 25 20 15 10 5 Age (years) % Estimated start of sexual life 0 5 10 15 20 25 30 35 40 45 50 55 60 65 70 75 Frequency Papillomavirus Infection (all types) Prophylactic HPV Vaccine Approved for Adolescent Girls *Routine vaccination for 11-12 year old females Females aged 13-17 years US 2009: 44.3% (42.4%-46.1%) for 1+ dose 26.7% (25.2%-28.3%) for 3 doses completed August 20, 2010 / 59(32);1018-1023 HPV Vaccine Coverage National Immunization Survey-Teen Continued Need for Screening Following HPV Vaccination ~70% ~50% ~14-25% HPV Type Specific Prevalence in All Cases ICC data: Smith et al. Int Journal of Cancer, 2007, 121 (3), 621-32. HSIL data: Smith et al. Int Journal of Cancer, 2007, 121 (3), 621-32. LSIL data: Clifford et al. Cancer Epidemiol Biomarkers. 2005;14:1157-1164 Decrease in Cervical Cancer Mortality Following Introduction of Pap Test in the United States 1. OBGYN.net. Available at: http://www.obgyn.net/displayarticle.asp?page=/yw/articles/braun_PAP 2. American Cancer Society. Cancer Facts & Figures. Available at: http://www.cancer.org/ Sensitivity of Cervical Cancer Screening Methods Naucler P, et al. JNCI. 2009;101:88-99. 30-64 Years 21-29 Years <21 Years No routine Pap smear Pap Smear Guidelines: 2009 American College of Obstetrics and Gynecology Pap smear every 3 years ..if patient has had 3 or more normal Pap results in a row, no abnormal test results in 10 years, and lacks other risk factors.* *History of cervical cancer or DES in utero, HIV positive, immunosuppression, or other risk factors for acquiring STDs. Bi-annual Pap smear ACOG Practice Bulletin No. 109. Obstet Gynecol. 2009;114:1409-20. ≥65 Years Consider discontinuing Pap smear at 65 or 70 years ..if patient has had 3 or more normal Pap results in a row, no abnormal test results in 10 years, and lacks other risk factors.* We can Change the Dialogue We can End Cervical Cancer Policy Makers Vaccination Screening We can Effect Real Change at the State-Level ALASKA HAWAII DC Age-adjusted Death Rates per 100,000 Quantile Interval 3.0 – 3.7 2.8 – 2.9 2.5 – 2.7 2.2 – 2.4 1.9 – 2.1 1.5 – 1.8 US Rate 2.5 Age-adjusted Mortality Rates per 100,000, 2001-2005 SEER Data SEER = Surveillance, Epidemiology, and End Results 1. Surveillance, Epidemiology and End Results (SEER) Cancer Stats NCI, 2001-2005. California Indiana Texas North Carolina Alabama Kentucky
Slide 14 - Jennifer S. Smith University of North Carolina JenniferS@unc.edu Cervical Cancer-Free America Initiative Overview Changing the Dialogue about Cervical Cancer Prevention Carolina Framework for Action against Cervical Cancer There are four key challenges to eradication of cervical cancer that a comprehensive public health strategy can address: HPV infection Lack of screening Screening errors Not receiving follow-up care for abnormal Pap smear results Brewer and Smith HPV virus-like particles (VLPs): Basis of HPV vaccination For Prevention of Cervical Cancer: Persistent HPV 16/18 infections HPV 16/18 abnormal pap smear HPV Types by Cervical Status: Potential Impact of 16/18 Vaccine ~70% ~50% ~14-25% HPV Type Specific Prevalence in All Cases ICC data: Smith et al. Int Journal of Cancer, 2007, 121 (3), 621-32. HSIL data: Smith et al. Int Journal of Cancer, 2007, 121 (3), 621-32. LSIL data: Clifford et al. Cancer Epidemiol Biomarkers. 2005;14:1157-1164 Optimal to Vaccinate Adolescent Girls before Sexual Debut 1- Hypothetical distribution of HPV prevalence in EU modeled after data available in the US and Canada 35 30 25 20 15 10 5 Age (years) % Estimated start of sexual life 0 5 10 15 20 25 30 35 40 45 50 55 60 65 70 75 Frequency Papillomavirus Infection (all types) Prophylactic HPV Vaccine Approved for Adolescent Girls *Routine vaccination for 11-12 year old females Females aged 13-17 years US 2009: 44.3% (42.4%-46.1%) for 1+ dose 26.7% (25.2%-28.3%) for 3 doses completed August 20, 2010 / 59(32);1018-1023 HPV Vaccine Coverage National Immunization Survey-Teen Continued Need for Screening Following HPV Vaccination ~70% ~50% ~14-25% HPV Type Specific Prevalence in All Cases ICC data: Smith et al. Int Journal of Cancer, 2007, 121 (3), 621-32. HSIL data: Smith et al. Int Journal of Cancer, 2007, 121 (3), 621-32. LSIL data: Clifford et al. Cancer Epidemiol Biomarkers. 2005;14:1157-1164 Decrease in Cervical Cancer Mortality Following Introduction of Pap Test in the United States 1. OBGYN.net. Available at: http://www.obgyn.net/displayarticle.asp?page=/yw/articles/braun_PAP 2. American Cancer Society. Cancer Facts & Figures. Available at: http://www.cancer.org/ Sensitivity of Cervical Cancer Screening Methods Naucler P, et al. JNCI. 2009;101:88-99. 30-64 Years 21-29 Years <21 Years No routine Pap smear Pap Smear Guidelines: 2009 American College of Obstetrics and Gynecology Pap smear every 3 years ..if patient has had 3 or more normal Pap results in a row, no abnormal test results in 10 years, and lacks other risk factors.* *History of cervical cancer or DES in utero, HIV positive, immunosuppression, or other risk factors for acquiring STDs. Bi-annual Pap smear ACOG Practice Bulletin No. 109. Obstet Gynecol. 2009;114:1409-20. ≥65 Years Consider discontinuing Pap smear at 65 or 70 years ..if patient has had 3 or more normal Pap results in a row, no abnormal test results in 10 years, and lacks other risk factors.* We can Change the Dialogue We can End Cervical Cancer Policy Makers Vaccination Screening We can Effect Real Change at the State-Level ALASKA HAWAII DC Age-adjusted Death Rates per 100,000 Quantile Interval 3.0 – 3.7 2.8 – 2.9 2.5 – 2.7 2.2 – 2.4 1.9 – 2.1 1.5 – 1.8 US Rate 2.5 Age-adjusted Mortality Rates per 100,000, 2001-2005 SEER Data SEER = Surveillance, Epidemiology, and End Results 1. Surveillance, Epidemiology and End Results (SEER) Cancer Stats NCI, 2001-2005. California Indiana Texas North Carolina Alabama Kentucky Cervical Cancer Free America Common State Goals To increase HPV vaccination among young female adolescents ages 10-18 To increase cervical cancer screening among women ages 25-70 who have not been screened in the last four years   .
Slide 15 - Jennifer S. Smith University of North Carolina JenniferS@unc.edu Cervical Cancer-Free America Initiative Overview Changing the Dialogue about Cervical Cancer Prevention Carolina Framework for Action against Cervical Cancer There are four key challenges to eradication of cervical cancer that a comprehensive public health strategy can address: HPV infection Lack of screening Screening errors Not receiving follow-up care for abnormal Pap smear results Brewer and Smith HPV virus-like particles (VLPs): Basis of HPV vaccination For Prevention of Cervical Cancer: Persistent HPV 16/18 infections HPV 16/18 abnormal pap smear HPV Types by Cervical Status: Potential Impact of 16/18 Vaccine ~70% ~50% ~14-25% HPV Type Specific Prevalence in All Cases ICC data: Smith et al. Int Journal of Cancer, 2007, 121 (3), 621-32. HSIL data: Smith et al. Int Journal of Cancer, 2007, 121 (3), 621-32. LSIL data: Clifford et al. Cancer Epidemiol Biomarkers. 2005;14:1157-1164 Optimal to Vaccinate Adolescent Girls before Sexual Debut 1- Hypothetical distribution of HPV prevalence in EU modeled after data available in the US and Canada 35 30 25 20 15 10 5 Age (years) % Estimated start of sexual life 0 5 10 15 20 25 30 35 40 45 50 55 60 65 70 75 Frequency Papillomavirus Infection (all types) Prophylactic HPV Vaccine Approved for Adolescent Girls *Routine vaccination for 11-12 year old females Females aged 13-17 years US 2009: 44.3% (42.4%-46.1%) for 1+ dose 26.7% (25.2%-28.3%) for 3 doses completed August 20, 2010 / 59(32);1018-1023 HPV Vaccine Coverage National Immunization Survey-Teen Continued Need for Screening Following HPV Vaccination ~70% ~50% ~14-25% HPV Type Specific Prevalence in All Cases ICC data: Smith et al. Int Journal of Cancer, 2007, 121 (3), 621-32. HSIL data: Smith et al. Int Journal of Cancer, 2007, 121 (3), 621-32. LSIL data: Clifford et al. Cancer Epidemiol Biomarkers. 2005;14:1157-1164 Decrease in Cervical Cancer Mortality Following Introduction of Pap Test in the United States 1. OBGYN.net. Available at: http://www.obgyn.net/displayarticle.asp?page=/yw/articles/braun_PAP 2. American Cancer Society. Cancer Facts & Figures. Available at: http://www.cancer.org/ Sensitivity of Cervical Cancer Screening Methods Naucler P, et al. JNCI. 2009;101:88-99. 30-64 Years 21-29 Years <21 Years No routine Pap smear Pap Smear Guidelines: 2009 American College of Obstetrics and Gynecology Pap smear every 3 years ..if patient has had 3 or more normal Pap results in a row, no abnormal test results in 10 years, and lacks other risk factors.* *History of cervical cancer or DES in utero, HIV positive, immunosuppression, or other risk factors for acquiring STDs. Bi-annual Pap smear ACOG Practice Bulletin No. 109. Obstet Gynecol. 2009;114:1409-20. ≥65 Years Consider discontinuing Pap smear at 65 or 70 years ..if patient has had 3 or more normal Pap results in a row, no abnormal test results in 10 years, and lacks other risk factors.* We can Change the Dialogue We can End Cervical Cancer Policy Makers Vaccination Screening We can Effect Real Change at the State-Level ALASKA HAWAII DC Age-adjusted Death Rates per 100,000 Quantile Interval 3.0 – 3.7 2.8 – 2.9 2.5 – 2.7 2.2 – 2.4 1.9 – 2.1 1.5 – 1.8 US Rate 2.5 Age-adjusted Mortality Rates per 100,000, 2001-2005 SEER Data SEER = Surveillance, Epidemiology, and End Results 1. Surveillance, Epidemiology and End Results (SEER) Cancer Stats NCI, 2001-2005. California Indiana Texas North Carolina Alabama Kentucky Cervical Cancer Free America Common State Goals To increase HPV vaccination among young female adolescents ages 10-18 To increase cervical cancer screening among women ages 25-70 who have not been screened in the last four years   . Cervical Cancer Free California California Medical Association Foundation Sara Cook, Carol Lee, Elissa Maas
Slide 16 - Jennifer S. Smith University of North Carolina JenniferS@unc.edu Cervical Cancer-Free America Initiative Overview Changing the Dialogue about Cervical Cancer Prevention Carolina Framework for Action against Cervical Cancer There are four key challenges to eradication of cervical cancer that a comprehensive public health strategy can address: HPV infection Lack of screening Screening errors Not receiving follow-up care for abnormal Pap smear results Brewer and Smith HPV virus-like particles (VLPs): Basis of HPV vaccination For Prevention of Cervical Cancer: Persistent HPV 16/18 infections HPV 16/18 abnormal pap smear HPV Types by Cervical Status: Potential Impact of 16/18 Vaccine ~70% ~50% ~14-25% HPV Type Specific Prevalence in All Cases ICC data: Smith et al. Int Journal of Cancer, 2007, 121 (3), 621-32. HSIL data: Smith et al. Int Journal of Cancer, 2007, 121 (3), 621-32. LSIL data: Clifford et al. Cancer Epidemiol Biomarkers. 2005;14:1157-1164 Optimal to Vaccinate Adolescent Girls before Sexual Debut 1- Hypothetical distribution of HPV prevalence in EU modeled after data available in the US and Canada 35 30 25 20 15 10 5 Age (years) % Estimated start of sexual life 0 5 10 15 20 25 30 35 40 45 50 55 60 65 70 75 Frequency Papillomavirus Infection (all types) Prophylactic HPV Vaccine Approved for Adolescent Girls *Routine vaccination for 11-12 year old females Females aged 13-17 years US 2009: 44.3% (42.4%-46.1%) for 1+ dose 26.7% (25.2%-28.3%) for 3 doses completed August 20, 2010 / 59(32);1018-1023 HPV Vaccine Coverage National Immunization Survey-Teen Continued Need for Screening Following HPV Vaccination ~70% ~50% ~14-25% HPV Type Specific Prevalence in All Cases ICC data: Smith et al. Int Journal of Cancer, 2007, 121 (3), 621-32. HSIL data: Smith et al. Int Journal of Cancer, 2007, 121 (3), 621-32. LSIL data: Clifford et al. Cancer Epidemiol Biomarkers. 2005;14:1157-1164 Decrease in Cervical Cancer Mortality Following Introduction of Pap Test in the United States 1. OBGYN.net. Available at: http://www.obgyn.net/displayarticle.asp?page=/yw/articles/braun_PAP 2. American Cancer Society. Cancer Facts & Figures. Available at: http://www.cancer.org/ Sensitivity of Cervical Cancer Screening Methods Naucler P, et al. JNCI. 2009;101:88-99. 30-64 Years 21-29 Years <21 Years No routine Pap smear Pap Smear Guidelines: 2009 American College of Obstetrics and Gynecology Pap smear every 3 years ..if patient has had 3 or more normal Pap results in a row, no abnormal test results in 10 years, and lacks other risk factors.* *History of cervical cancer or DES in utero, HIV positive, immunosuppression, or other risk factors for acquiring STDs. Bi-annual Pap smear ACOG Practice Bulletin No. 109. Obstet Gynecol. 2009;114:1409-20. ≥65 Years Consider discontinuing Pap smear at 65 or 70 years ..if patient has had 3 or more normal Pap results in a row, no abnormal test results in 10 years, and lacks other risk factors.* We can Change the Dialogue We can End Cervical Cancer Policy Makers Vaccination Screening We can Effect Real Change at the State-Level ALASKA HAWAII DC Age-adjusted Death Rates per 100,000 Quantile Interval 3.0 – 3.7 2.8 – 2.9 2.5 – 2.7 2.2 – 2.4 1.9 – 2.1 1.5 – 1.8 US Rate 2.5 Age-adjusted Mortality Rates per 100,000, 2001-2005 SEER Data SEER = Surveillance, Epidemiology, and End Results 1. Surveillance, Epidemiology and End Results (SEER) Cancer Stats NCI, 2001-2005. California Indiana Texas North Carolina Alabama Kentucky Cervical Cancer Free America Common State Goals To increase HPV vaccination among young female adolescents ages 10-18 To increase cervical cancer screening among women ages 25-70 who have not been screened in the last four years   . Cervical Cancer Free California California Medical Association Foundation Sara Cook, Carol Lee, Elissa Maas Cervical Cancer Free Alabama University of Alabama Mona Fouad, Warner Huh, Theresa Wynn
Slide 17 - Jennifer S. Smith University of North Carolina JenniferS@unc.edu Cervical Cancer-Free America Initiative Overview Changing the Dialogue about Cervical Cancer Prevention Carolina Framework for Action against Cervical Cancer There are four key challenges to eradication of cervical cancer that a comprehensive public health strategy can address: HPV infection Lack of screening Screening errors Not receiving follow-up care for abnormal Pap smear results Brewer and Smith HPV virus-like particles (VLPs): Basis of HPV vaccination For Prevention of Cervical Cancer: Persistent HPV 16/18 infections HPV 16/18 abnormal pap smear HPV Types by Cervical Status: Potential Impact of 16/18 Vaccine ~70% ~50% ~14-25% HPV Type Specific Prevalence in All Cases ICC data: Smith et al. Int Journal of Cancer, 2007, 121 (3), 621-32. HSIL data: Smith et al. Int Journal of Cancer, 2007, 121 (3), 621-32. LSIL data: Clifford et al. Cancer Epidemiol Biomarkers. 2005;14:1157-1164 Optimal to Vaccinate Adolescent Girls before Sexual Debut 1- Hypothetical distribution of HPV prevalence in EU modeled after data available in the US and Canada 35 30 25 20 15 10 5 Age (years) % Estimated start of sexual life 0 5 10 15 20 25 30 35 40 45 50 55 60 65 70 75 Frequency Papillomavirus Infection (all types) Prophylactic HPV Vaccine Approved for Adolescent Girls *Routine vaccination for 11-12 year old females Females aged 13-17 years US 2009: 44.3% (42.4%-46.1%) for 1+ dose 26.7% (25.2%-28.3%) for 3 doses completed August 20, 2010 / 59(32);1018-1023 HPV Vaccine Coverage National Immunization Survey-Teen Continued Need for Screening Following HPV Vaccination ~70% ~50% ~14-25% HPV Type Specific Prevalence in All Cases ICC data: Smith et al. Int Journal of Cancer, 2007, 121 (3), 621-32. HSIL data: Smith et al. Int Journal of Cancer, 2007, 121 (3), 621-32. LSIL data: Clifford et al. Cancer Epidemiol Biomarkers. 2005;14:1157-1164 Decrease in Cervical Cancer Mortality Following Introduction of Pap Test in the United States 1. OBGYN.net. Available at: http://www.obgyn.net/displayarticle.asp?page=/yw/articles/braun_PAP 2. American Cancer Society. Cancer Facts & Figures. Available at: http://www.cancer.org/ Sensitivity of Cervical Cancer Screening Methods Naucler P, et al. JNCI. 2009;101:88-99. 30-64 Years 21-29 Years <21 Years No routine Pap smear Pap Smear Guidelines: 2009 American College of Obstetrics and Gynecology Pap smear every 3 years ..if patient has had 3 or more normal Pap results in a row, no abnormal test results in 10 years, and lacks other risk factors.* *History of cervical cancer or DES in utero, HIV positive, immunosuppression, or other risk factors for acquiring STDs. Bi-annual Pap smear ACOG Practice Bulletin No. 109. Obstet Gynecol. 2009;114:1409-20. ≥65 Years Consider discontinuing Pap smear at 65 or 70 years ..if patient has had 3 or more normal Pap results in a row, no abnormal test results in 10 years, and lacks other risk factors.* We can Change the Dialogue We can End Cervical Cancer Policy Makers Vaccination Screening We can Effect Real Change at the State-Level ALASKA HAWAII DC Age-adjusted Death Rates per 100,000 Quantile Interval 3.0 – 3.7 2.8 – 2.9 2.5 – 2.7 2.2 – 2.4 1.9 – 2.1 1.5 – 1.8 US Rate 2.5 Age-adjusted Mortality Rates per 100,000, 2001-2005 SEER Data SEER = Surveillance, Epidemiology, and End Results 1. Surveillance, Epidemiology and End Results (SEER) Cancer Stats NCI, 2001-2005. California Indiana Texas North Carolina Alabama Kentucky Cervical Cancer Free America Common State Goals To increase HPV vaccination among young female adolescents ages 10-18 To increase cervical cancer screening among women ages 25-70 who have not been screened in the last four years   . Cervical Cancer Free California California Medical Association Foundation Sara Cook, Carol Lee, Elissa Maas Cervical Cancer Free Alabama University of Alabama Mona Fouad, Warner Huh, Theresa Wynn Cervical Cancer Free Kentucky University of Kentucky Baretta Casey, Rick Crosby, Robin Vanderpool
Slide 18 - Jennifer S. Smith University of North Carolina JenniferS@unc.edu Cervical Cancer-Free America Initiative Overview Changing the Dialogue about Cervical Cancer Prevention Carolina Framework for Action against Cervical Cancer There are four key challenges to eradication of cervical cancer that a comprehensive public health strategy can address: HPV infection Lack of screening Screening errors Not receiving follow-up care for abnormal Pap smear results Brewer and Smith HPV virus-like particles (VLPs): Basis of HPV vaccination For Prevention of Cervical Cancer: Persistent HPV 16/18 infections HPV 16/18 abnormal pap smear HPV Types by Cervical Status: Potential Impact of 16/18 Vaccine ~70% ~50% ~14-25% HPV Type Specific Prevalence in All Cases ICC data: Smith et al. Int Journal of Cancer, 2007, 121 (3), 621-32. HSIL data: Smith et al. Int Journal of Cancer, 2007, 121 (3), 621-32. LSIL data: Clifford et al. Cancer Epidemiol Biomarkers. 2005;14:1157-1164 Optimal to Vaccinate Adolescent Girls before Sexual Debut 1- Hypothetical distribution of HPV prevalence in EU modeled after data available in the US and Canada 35 30 25 20 15 10 5 Age (years) % Estimated start of sexual life 0 5 10 15 20 25 30 35 40 45 50 55 60 65 70 75 Frequency Papillomavirus Infection (all types) Prophylactic HPV Vaccine Approved for Adolescent Girls *Routine vaccination for 11-12 year old females Females aged 13-17 years US 2009: 44.3% (42.4%-46.1%) for 1+ dose 26.7% (25.2%-28.3%) for 3 doses completed August 20, 2010 / 59(32);1018-1023 HPV Vaccine Coverage National Immunization Survey-Teen Continued Need for Screening Following HPV Vaccination ~70% ~50% ~14-25% HPV Type Specific Prevalence in All Cases ICC data: Smith et al. Int Journal of Cancer, 2007, 121 (3), 621-32. HSIL data: Smith et al. Int Journal of Cancer, 2007, 121 (3), 621-32. LSIL data: Clifford et al. Cancer Epidemiol Biomarkers. 2005;14:1157-1164 Decrease in Cervical Cancer Mortality Following Introduction of Pap Test in the United States 1. OBGYN.net. Available at: http://www.obgyn.net/displayarticle.asp?page=/yw/articles/braun_PAP 2. American Cancer Society. Cancer Facts & Figures. Available at: http://www.cancer.org/ Sensitivity of Cervical Cancer Screening Methods Naucler P, et al. JNCI. 2009;101:88-99. 30-64 Years 21-29 Years <21 Years No routine Pap smear Pap Smear Guidelines: 2009 American College of Obstetrics and Gynecology Pap smear every 3 years ..if patient has had 3 or more normal Pap results in a row, no abnormal test results in 10 years, and lacks other risk factors.* *History of cervical cancer or DES in utero, HIV positive, immunosuppression, or other risk factors for acquiring STDs. Bi-annual Pap smear ACOG Practice Bulletin No. 109. Obstet Gynecol. 2009;114:1409-20. ≥65 Years Consider discontinuing Pap smear at 65 or 70 years ..if patient has had 3 or more normal Pap results in a row, no abnormal test results in 10 years, and lacks other risk factors.* We can Change the Dialogue We can End Cervical Cancer Policy Makers Vaccination Screening We can Effect Real Change at the State-Level ALASKA HAWAII DC Age-adjusted Death Rates per 100,000 Quantile Interval 3.0 – 3.7 2.8 – 2.9 2.5 – 2.7 2.2 – 2.4 1.9 – 2.1 1.5 – 1.8 US Rate 2.5 Age-adjusted Mortality Rates per 100,000, 2001-2005 SEER Data SEER = Surveillance, Epidemiology, and End Results 1. Surveillance, Epidemiology and End Results (SEER) Cancer Stats NCI, 2001-2005. California Indiana Texas North Carolina Alabama Kentucky Cervical Cancer Free America Common State Goals To increase HPV vaccination among young female adolescents ages 10-18 To increase cervical cancer screening among women ages 25-70 who have not been screened in the last four years   . Cervical Cancer Free California California Medical Association Foundation Sara Cook, Carol Lee, Elissa Maas Cervical Cancer Free Alabama University of Alabama Mona Fouad, Warner Huh, Theresa Wynn Cervical Cancer Free Kentucky University of Kentucky Baretta Casey, Rick Crosby, Robin Vanderpool Cervical Cancer Free Indiana University of Indiana Gregory Zimet Kirk Forbes
Slide 19 - Jennifer S. Smith University of North Carolina JenniferS@unc.edu Cervical Cancer-Free America Initiative Overview Changing the Dialogue about Cervical Cancer Prevention Carolina Framework for Action against Cervical Cancer There are four key challenges to eradication of cervical cancer that a comprehensive public health strategy can address: HPV infection Lack of screening Screening errors Not receiving follow-up care for abnormal Pap smear results Brewer and Smith HPV virus-like particles (VLPs): Basis of HPV vaccination For Prevention of Cervical Cancer: Persistent HPV 16/18 infections HPV 16/18 abnormal pap smear HPV Types by Cervical Status: Potential Impact of 16/18 Vaccine ~70% ~50% ~14-25% HPV Type Specific Prevalence in All Cases ICC data: Smith et al. Int Journal of Cancer, 2007, 121 (3), 621-32. HSIL data: Smith et al. Int Journal of Cancer, 2007, 121 (3), 621-32. LSIL data: Clifford et al. Cancer Epidemiol Biomarkers. 2005;14:1157-1164 Optimal to Vaccinate Adolescent Girls before Sexual Debut 1- Hypothetical distribution of HPV prevalence in EU modeled after data available in the US and Canada 35 30 25 20 15 10 5 Age (years) % Estimated start of sexual life 0 5 10 15 20 25 30 35 40 45 50 55 60 65 70 75 Frequency Papillomavirus Infection (all types) Prophylactic HPV Vaccine Approved for Adolescent Girls *Routine vaccination for 11-12 year old females Females aged 13-17 years US 2009: 44.3% (42.4%-46.1%) for 1+ dose 26.7% (25.2%-28.3%) for 3 doses completed August 20, 2010 / 59(32);1018-1023 HPV Vaccine Coverage National Immunization Survey-Teen Continued Need for Screening Following HPV Vaccination ~70% ~50% ~14-25% HPV Type Specific Prevalence in All Cases ICC data: Smith et al. Int Journal of Cancer, 2007, 121 (3), 621-32. HSIL data: Smith et al. Int Journal of Cancer, 2007, 121 (3), 621-32. LSIL data: Clifford et al. Cancer Epidemiol Biomarkers. 2005;14:1157-1164 Decrease in Cervical Cancer Mortality Following Introduction of Pap Test in the United States 1. OBGYN.net. Available at: http://www.obgyn.net/displayarticle.asp?page=/yw/articles/braun_PAP 2. American Cancer Society. Cancer Facts & Figures. Available at: http://www.cancer.org/ Sensitivity of Cervical Cancer Screening Methods Naucler P, et al. JNCI. 2009;101:88-99. 30-64 Years 21-29 Years <21 Years No routine Pap smear Pap Smear Guidelines: 2009 American College of Obstetrics and Gynecology Pap smear every 3 years ..if patient has had 3 or more normal Pap results in a row, no abnormal test results in 10 years, and lacks other risk factors.* *History of cervical cancer or DES in utero, HIV positive, immunosuppression, or other risk factors for acquiring STDs. Bi-annual Pap smear ACOG Practice Bulletin No. 109. Obstet Gynecol. 2009;114:1409-20. ≥65 Years Consider discontinuing Pap smear at 65 or 70 years ..if patient has had 3 or more normal Pap results in a row, no abnormal test results in 10 years, and lacks other risk factors.* We can Change the Dialogue We can End Cervical Cancer Policy Makers Vaccination Screening We can Effect Real Change at the State-Level ALASKA HAWAII DC Age-adjusted Death Rates per 100,000 Quantile Interval 3.0 – 3.7 2.8 – 2.9 2.5 – 2.7 2.2 – 2.4 1.9 – 2.1 1.5 – 1.8 US Rate 2.5 Age-adjusted Mortality Rates per 100,000, 2001-2005 SEER Data SEER = Surveillance, Epidemiology, and End Results 1. Surveillance, Epidemiology and End Results (SEER) Cancer Stats NCI, 2001-2005. California Indiana Texas North Carolina Alabama Kentucky Cervical Cancer Free America Common State Goals To increase HPV vaccination among young female adolescents ages 10-18 To increase cervical cancer screening among women ages 25-70 who have not been screened in the last four years   . Cervical Cancer Free California California Medical Association Foundation Sara Cook, Carol Lee, Elissa Maas Cervical Cancer Free Alabama University of Alabama Mona Fouad, Warner Huh, Theresa Wynn Cervical Cancer Free Kentucky University of Kentucky Baretta Casey, Rick Crosby, Robin Vanderpool Cervical Cancer Free Indiana University of Indiana Gregory Zimet Kirk Forbes Cervical Cancer Free North Carolina University of North Carolina Noel Brewer, Pamela Entzel, Jennifer Smith
Slide 20 - Jennifer S. Smith University of North Carolina JenniferS@unc.edu Cervical Cancer-Free America Initiative Overview Changing the Dialogue about Cervical Cancer Prevention Carolina Framework for Action against Cervical Cancer There are four key challenges to eradication of cervical cancer that a comprehensive public health strategy can address: HPV infection Lack of screening Screening errors Not receiving follow-up care for abnormal Pap smear results Brewer and Smith HPV virus-like particles (VLPs): Basis of HPV vaccination For Prevention of Cervical Cancer: Persistent HPV 16/18 infections HPV 16/18 abnormal pap smear HPV Types by Cervical Status: Potential Impact of 16/18 Vaccine ~70% ~50% ~14-25% HPV Type Specific Prevalence in All Cases ICC data: Smith et al. Int Journal of Cancer, 2007, 121 (3), 621-32. HSIL data: Smith et al. Int Journal of Cancer, 2007, 121 (3), 621-32. LSIL data: Clifford et al. Cancer Epidemiol Biomarkers. 2005;14:1157-1164 Optimal to Vaccinate Adolescent Girls before Sexual Debut 1- Hypothetical distribution of HPV prevalence in EU modeled after data available in the US and Canada 35 30 25 20 15 10 5 Age (years) % Estimated start of sexual life 0 5 10 15 20 25 30 35 40 45 50 55 60 65 70 75 Frequency Papillomavirus Infection (all types) Prophylactic HPV Vaccine Approved for Adolescent Girls *Routine vaccination for 11-12 year old females Females aged 13-17 years US 2009: 44.3% (42.4%-46.1%) for 1+ dose 26.7% (25.2%-28.3%) for 3 doses completed August 20, 2010 / 59(32);1018-1023 HPV Vaccine Coverage National Immunization Survey-Teen Continued Need for Screening Following HPV Vaccination ~70% ~50% ~14-25% HPV Type Specific Prevalence in All Cases ICC data: Smith et al. Int Journal of Cancer, 2007, 121 (3), 621-32. HSIL data: Smith et al. Int Journal of Cancer, 2007, 121 (3), 621-32. LSIL data: Clifford et al. Cancer Epidemiol Biomarkers. 2005;14:1157-1164 Decrease in Cervical Cancer Mortality Following Introduction of Pap Test in the United States 1. OBGYN.net. Available at: http://www.obgyn.net/displayarticle.asp?page=/yw/articles/braun_PAP 2. American Cancer Society. Cancer Facts & Figures. Available at: http://www.cancer.org/ Sensitivity of Cervical Cancer Screening Methods Naucler P, et al. JNCI. 2009;101:88-99. 30-64 Years 21-29 Years <21 Years No routine Pap smear Pap Smear Guidelines: 2009 American College of Obstetrics and Gynecology Pap smear every 3 years ..if patient has had 3 or more normal Pap results in a row, no abnormal test results in 10 years, and lacks other risk factors.* *History of cervical cancer or DES in utero, HIV positive, immunosuppression, or other risk factors for acquiring STDs. Bi-annual Pap smear ACOG Practice Bulletin No. 109. Obstet Gynecol. 2009;114:1409-20. ≥65 Years Consider discontinuing Pap smear at 65 or 70 years ..if patient has had 3 or more normal Pap results in a row, no abnormal test results in 10 years, and lacks other risk factors.* We can Change the Dialogue We can End Cervical Cancer Policy Makers Vaccination Screening We can Effect Real Change at the State-Level ALASKA HAWAII DC Age-adjusted Death Rates per 100,000 Quantile Interval 3.0 – 3.7 2.8 – 2.9 2.5 – 2.7 2.2 – 2.4 1.9 – 2.1 1.5 – 1.8 US Rate 2.5 Age-adjusted Mortality Rates per 100,000, 2001-2005 SEER Data SEER = Surveillance, Epidemiology, and End Results 1. Surveillance, Epidemiology and End Results (SEER) Cancer Stats NCI, 2001-2005. California Indiana Texas North Carolina Alabama Kentucky Cervical Cancer Free America Common State Goals To increase HPV vaccination among young female adolescents ages 10-18 To increase cervical cancer screening among women ages 25-70 who have not been screened in the last four years   . Cervical Cancer Free California California Medical Association Foundation Sara Cook, Carol Lee, Elissa Maas Cervical Cancer Free Alabama University of Alabama Mona Fouad, Warner Huh, Theresa Wynn Cervical Cancer Free Kentucky University of Kentucky Baretta Casey, Rick Crosby, Robin Vanderpool Cervical Cancer Free Indiana University of Indiana Gregory Zimet Kirk Forbes Cervical Cancer Free North Carolina University of North Carolina Noel Brewer, Pamela Entzel, Jennifer Smith How Can We Work Actively Together? January: Cervical Cancer Awareness Month is right around the corner.
Slide 21 - Jennifer S. Smith University of North Carolina JenniferS@unc.edu Cervical Cancer-Free America Initiative Overview Changing the Dialogue about Cervical Cancer Prevention Carolina Framework for Action against Cervical Cancer There are four key challenges to eradication of cervical cancer that a comprehensive public health strategy can address: HPV infection Lack of screening Screening errors Not receiving follow-up care for abnormal Pap smear results Brewer and Smith HPV virus-like particles (VLPs): Basis of HPV vaccination For Prevention of Cervical Cancer: Persistent HPV 16/18 infections HPV 16/18 abnormal pap smear HPV Types by Cervical Status: Potential Impact of 16/18 Vaccine ~70% ~50% ~14-25% HPV Type Specific Prevalence in All Cases ICC data: Smith et al. Int Journal of Cancer, 2007, 121 (3), 621-32. HSIL data: Smith et al. Int Journal of Cancer, 2007, 121 (3), 621-32. LSIL data: Clifford et al. Cancer Epidemiol Biomarkers. 2005;14:1157-1164 Optimal to Vaccinate Adolescent Girls before Sexual Debut 1- Hypothetical distribution of HPV prevalence in EU modeled after data available in the US and Canada 35 30 25 20 15 10 5 Age (years) % Estimated start of sexual life 0 5 10 15 20 25 30 35 40 45 50 55 60 65 70 75 Frequency Papillomavirus Infection (all types) Prophylactic HPV Vaccine Approved for Adolescent Girls *Routine vaccination for 11-12 year old females Females aged 13-17 years US 2009: 44.3% (42.4%-46.1%) for 1+ dose 26.7% (25.2%-28.3%) for 3 doses completed August 20, 2010 / 59(32);1018-1023 HPV Vaccine Coverage National Immunization Survey-Teen Continued Need for Screening Following HPV Vaccination ~70% ~50% ~14-25% HPV Type Specific Prevalence in All Cases ICC data: Smith et al. Int Journal of Cancer, 2007, 121 (3), 621-32. HSIL data: Smith et al. Int Journal of Cancer, 2007, 121 (3), 621-32. LSIL data: Clifford et al. Cancer Epidemiol Biomarkers. 2005;14:1157-1164 Decrease in Cervical Cancer Mortality Following Introduction of Pap Test in the United States 1. OBGYN.net. Available at: http://www.obgyn.net/displayarticle.asp?page=/yw/articles/braun_PAP 2. American Cancer Society. Cancer Facts & Figures. Available at: http://www.cancer.org/ Sensitivity of Cervical Cancer Screening Methods Naucler P, et al. JNCI. 2009;101:88-99. 30-64 Years 21-29 Years <21 Years No routine Pap smear Pap Smear Guidelines: 2009 American College of Obstetrics and Gynecology Pap smear every 3 years ..if patient has had 3 or more normal Pap results in a row, no abnormal test results in 10 years, and lacks other risk factors.* *History of cervical cancer or DES in utero, HIV positive, immunosuppression, or other risk factors for acquiring STDs. Bi-annual Pap smear ACOG Practice Bulletin No. 109. Obstet Gynecol. 2009;114:1409-20. ≥65 Years Consider discontinuing Pap smear at 65 or 70 years ..if patient has had 3 or more normal Pap results in a row, no abnormal test results in 10 years, and lacks other risk factors.* We can Change the Dialogue We can End Cervical Cancer Policy Makers Vaccination Screening We can Effect Real Change at the State-Level ALASKA HAWAII DC Age-adjusted Death Rates per 100,000 Quantile Interval 3.0 – 3.7 2.8 – 2.9 2.5 – 2.7 2.2 – 2.4 1.9 – 2.1 1.5 – 1.8 US Rate 2.5 Age-adjusted Mortality Rates per 100,000, 2001-2005 SEER Data SEER = Surveillance, Epidemiology, and End Results 1. Surveillance, Epidemiology and End Results (SEER) Cancer Stats NCI, 2001-2005. California Indiana Texas North Carolina Alabama Kentucky Cervical Cancer Free America Common State Goals To increase HPV vaccination among young female adolescents ages 10-18 To increase cervical cancer screening among women ages 25-70 who have not been screened in the last four years   . Cervical Cancer Free California California Medical Association Foundation Sara Cook, Carol Lee, Elissa Maas Cervical Cancer Free Alabama University of Alabama Mona Fouad, Warner Huh, Theresa Wynn Cervical Cancer Free Kentucky University of Kentucky Baretta Casey, Rick Crosby, Robin Vanderpool Cervical Cancer Free Indiana University of Indiana Gregory Zimet Kirk Forbes Cervical Cancer Free North Carolina University of North Carolina Noel Brewer, Pamela Entzel, Jennifer Smith How Can We Work Actively Together? January: Cervical Cancer Awareness Month is right around the corner.